Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7268MR)

This product GTTS-WQ7268MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7268MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5447MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ7367MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ10939MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ9045MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10500MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ8616MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ793MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW